Jun 08, 2015 8:42 am EDT Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
May 26, 2015 4:15 pm EDT Capricor Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 12, 2015 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
May 05, 2015 4:05 pm EDT Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
Apr 22, 2015 8:00 am EDT Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Apr 08, 2015 8:00 am EDT Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
Mar 31, 2015 8:00 am EDT Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
Mar 23, 2015 8:05 am EDT Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
Mar 18, 2015 4:05 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
Mar 12, 2015 8:00 am EDT Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT